Treatment with high dose of erythropoiesis-stimulating agents and mortality: Analysis with a sequential Cox approach and a marginal structural model

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 10, 2015, Pages 1068-1075

  Suttorp, Marit M ^a   Hoekstra, Tiny ^a   Mittelman, Moshe ^b   Ott, Ilka ^c   Krediet, Raymond T ^d   Dekker, Friedo W ^a   Putter, Hein ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Dialysis; Erythropoietin; Mortality; Pharmacoepidemiology

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; CREATININE; FERRITIN; HEMOGLOBIN; UREA;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MARGINAL STRUCTURAL MODEL; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT DURATION; UREA BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; DOSE RESPONSE; EPIDEMIOLOGY; MORTALITY; PHARMACOEPIDEMIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TRENDS;

ANEMIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; PHARMACOEPIDEMIOLOGY; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84942819890     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3855     Document Type: Article

References (27)

1. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
3. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
4. Bennett CL, Spiegel DM, Macdougall IC, et al. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost 2012; 38: 783-796.
5. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70.
6. Zhang Y, Thamer M, Cotter D, Kaufman J, Hernan MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4: 638-644.
7. Bradbury BD, Brookhart MA, Winkelmayer WC, et al. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations. Am J Kidney Dis 2009; 54: 554-560.
8. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
9. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168: 656-664.
10. Gran JM, Roysland K, Wolbers M, et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Stat Med 2010; 29: 2757-2768.
11. Wang O, Kilpatrick RD, Critchlow CW, et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010; 5: 182-188.
12. Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernan MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 2011; 80: 663-669.
13. Weinhandl ED, Gilbertson DT, Collins AJ. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of medicare hemodialysis patients. Am J Nephrol 2011; 34: 298-308.
14. de Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014; 74: 159-168.
15. van Dijk PC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16: 1120-1129.
16. Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. Adv Perit Dial 1999; 15: 222-225.
17. Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S. The analysis of competing events like cause-specific mortality - beware of the Kaplan-Meier method. Nephrol Dial Transplant 2011; 26: 56-61.
18. de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed 2010; 99: 261-274.
19. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11: 561-570.
20. Robins JM, Hernan MA. Estimation of the causal effects of time-varying exposures. In Longitudinal Data Analysis, Fitzmaurice G, Davidian M, Verbeke G, Molenberghs G (eds.). Chapman & Hall/CRC: Boca Raton: 2009; 553-597.
21. Bradbury BD, Do TP, Winkelmayer WC, Critchlow CW, Brookhart MA. Greater epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Pharmacoepidemiol Drug Saf 2009; 18: 932-940.
22. Yang W, Joffe MM, Feldman HI. Exploring the effect of erythropoietin on mortality using USRDS data. Pharmacoepidemiol Drug Saf 2013; 22: 593-606.
23. Oster HS, Neumann D, Hoffman M, Mittelman M. Erythropoietin: the swinging pendulum. Leuk Res 2012; 36: 939-944.
24. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045-4059.
25. Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012; 59: 108-116.
26. Fort J, Cuevas X, Garcia F, et al. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrol Dial Transplant 2010; 25: 2702-2710.
27. Strippoli GF. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010; 11: 70.